A state law passed during the 2021 RI General Assembly session which addressed out-of-pocket costs for insulin drugs. Effective 1 de janeiro, 2022, in accordance with RIGL § 27-20.8-3, copayments for insulin prescription drugs will not exceed $40 for each thirty-day supply and are not subject to a deductible.
Prescription drug claims for insulin submitted by participating pharmacies will be processed with a patient out-of-pocket charge for the lower of $40, the applicable prescription copayment, or pharmacy charge per month supply. All formulary-covered insulin products will be eligible for this benefit. Application of the benefit will not be limited or require satisfaction of any benefit-defined deductible.
BASAGLAR INJ 100UNIT
HUMULIN R INJ U-500
INSULIN ASPA INJ 100/ML
INSULIN ASPA INJ 70/30
LANTUS INJ 100/ML
LEVEMIR INJ
NOVOLIN INJ 70/30
NOVOLIN N INJ U-100
NOVOLIN R INJ U-100
NOVOLOG INJ 100/ML
NOVOLOG MIX - INJ 70/30
TOUJEO MAX INJ300IU/ML